menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: Long-Term Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based MCED Test

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2023 American Society of Clinical Oncology Annual Meeting unveiled key findings from the longitudinal analysis that was done on the DETECT-A study. Learn about the long-term clinical outcomes of patients who were diagnosed with cancer following detection by a blood-based multi-cancer early detection (MCED) test with Dr. Charles Turck and Mr. Adam Buchanan, Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania and co-author of the poster.

    This is a non-certified educational program produced and controlled by ReachMD and is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A poster presented at the 2023 American Society of Clinical Oncology Annual Meeting unveiled key findings from the longitudinal analysis that was done on the DETECT-A study. Learn about the long-term clinical outcomes of patients who were diagnosed with cancer following detection by a blood-based multi-cancer early detection (MCED) test with Dr. Charles Turck and Mr. Adam Buchanan, Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania and co-author of the poster.

    This is a non-certified educational program produced and controlled by ReachMD and is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Schedule3 Oct 2023